NexImmune Inc.

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.

Investing News NetworkYour trusted source for investing success

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

Rare Earths Stocks: 9 Biggest Companies in 2024

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

When is the Starlink IPO Date and Can You Invest? (Updated 2024)

Investing in Graphene Companies (Updated 2024)

SAGA Metals Reports Channel Sample Assay Results at Double Mer Uranium Project

Radiopharm achieves Nasdaq listing of ADS

HyProMag USA Feasibility Study Demonstrates Robust Economics and the Opportunity to Develop a Major New, Domestic Source of Recycled Rare Earths Magnets for the United States

Extension of Option to Acquire Major Nickel Asset

Trillion Energy Successfully Re-completes Wells in VS Program

FPX Nickel Leverages Strong Balance Sheet and Intends to Launch Normal Course Issuer Bid

Purpose Bitcoin ETF

Soma Gold Corp.

MP Materials Corp.

First Helium

2024 Gold Outlook Report

2024 Uranium Outlook: Australia Edition

2024 Lithium Market Outlook

2024 Uranium Outlook

NexImmune Inc.

Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, Euro 500 Million Share Buy-Back Program Launched

5 US Longevity and Anti-aging Stocks to Watch in 2024

Stem Cell Stocks: 10 Biggest NASDAQ Companies

Interactive Chart